IL155279A0 - Methods of treatment using wisp polypeptides - Google Patents

Methods of treatment using wisp polypeptides

Info

Publication number
IL155279A0
IL155279A0 IL15527901A IL15527901A IL155279A0 IL 155279 A0 IL155279 A0 IL 155279A0 IL 15527901 A IL15527901 A IL 15527901A IL 15527901 A IL15527901 A IL 15527901A IL 155279 A0 IL155279 A0 IL 155279A0
Authority
IL
Israel
Prior art keywords
treatment
administration
cartilage
injury
repair
Prior art date
Application number
IL15527901A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL155279A0 publication Critical patent/IL155279A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL15527901A 2000-10-16 2001-10-12 Methods of treatment using wisp polypeptides IL155279A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24122200P 2000-10-16 2000-10-16
PCT/US2001/032142 WO2002033085A2 (fr) 2000-10-16 2001-10-12 Techniques de traitement utilisant des polypeptides wisp

Publications (1)

Publication Number Publication Date
IL155279A0 true IL155279A0 (en) 2003-11-23

Family

ID=22909763

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15527901A IL155279A0 (en) 2000-10-16 2001-10-12 Methods of treatment using wisp polypeptides
IL155279A IL155279A (en) 2000-10-16 2003-04-08 Use of a wisp polypeptide for the preparation of medicaments for the treatment of mammalian cartilage cells or mammalian cartilage tissue damaged from a degenerative cartilagenous disorder or injury
IL200484A IL200484A (en) 2000-10-16 2009-08-19 Use of wisp polypeptides or biologically active fragment thereof for the preparation of medicaments for treatment of mammalian cartilage cells or tissue

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL155279A IL155279A (en) 2000-10-16 2003-04-08 Use of a wisp polypeptide for the preparation of medicaments for the treatment of mammalian cartilage cells or mammalian cartilage tissue damaged from a degenerative cartilagenous disorder or injury
IL200484A IL200484A (en) 2000-10-16 2009-08-19 Use of wisp polypeptides or biologically active fragment thereof for the preparation of medicaments for treatment of mammalian cartilage cells or tissue

Country Status (10)

Country Link
US (2) US7687460B2 (fr)
EP (3) EP1927659B1 (fr)
JP (1) JP4202128B2 (fr)
AT (3) ATE389719T1 (fr)
AU (2) AU2002224377B2 (fr)
CA (1) CA2425145C (fr)
DE (2) DE60133301T2 (fr)
ES (3) ES2381935T3 (fr)
IL (3) IL155279A0 (fr)
WO (1) WO2002033085A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2425145C (fr) * 2000-10-16 2011-08-30 Genentech, Inc. Procedes de traitement utilisant des polypeptides wisp
AU2004272066B8 (en) * 2003-09-11 2010-08-05 Genentech, Inc. Methods of using WISP antagonists
SE0401069D0 (sv) * 2004-04-26 2004-04-26 Anamar Medical Ab Use of Compounds for the Treatment of Diseases and Conditions
BRPI0713572A2 (pt) * 2006-06-20 2012-10-23 Stephen Duguay meios livres de soro e seus usos para expansão de condrócitos
EP2147311A4 (fr) * 2007-04-26 2010-08-11 Genera Istrazivanja D O O Biomarqueurs sanguins pour les fractures osseuses et les lesions cartilagineuses
AU2009234338B2 (en) 2008-01-18 2014-07-24 Burnham Institute For Medical Research Methods and compositions related to internalizing RGD peptides
EP2445536B1 (fr) 2009-06-22 2016-06-08 Burnham Institute for Medical Research Procédés et compositions utilisant des peptides et des protéines dotés d'éléments c-terminaux
PT2453921E (pt) 2009-07-14 2015-09-25 Novartis Ag Diferenciação de células estaminais mesenquimais
US20140037659A1 (en) * 2011-01-31 2014-02-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Snx9 as a novel biomarker for chronic inflammation and associated immunosuppresion and a new regulator of t cell receptor expression and function
HK1211037A1 (en) 2012-02-11 2016-05-13 霍夫曼-拉罗奇有限公司 R-spondin translocations and methods using the same
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation
AU2017207445B2 (en) * 2016-01-14 2023-12-07 Spinalcyte, Llc Cellular blend for the regeneration of chondrocytes or cartilage type cells
US10828347B2 (en) * 2016-06-02 2020-11-10 Societe Des Produits Nestle S.A. Methods for treating sarcopenia and muscle injury
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
EP3711772A1 (fr) * 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Protéines recombinantes et protéines de fusion
KR102167443B1 (ko) * 2019-03-25 2020-10-19 주식회사 카티프라임 체외 골관절염 모델 및 이를 이용한 골관절염 치료제 스크리닝 방법
CN111700881B (zh) * 2020-07-02 2021-05-18 四川大学 Wnt蛋白＼ZIF-8纳米复合体、其制备方法及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364839A (en) 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
US5206023A (en) 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5408040A (en) 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
EP0736034A4 (fr) 1993-12-22 1999-02-03 Merck & Co Inc Adn codant le facteur de croissance wnt-x
US5444047A (en) 1994-06-16 1995-08-22 Dipasquale; Gene Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
WO2000053753A2 (fr) * 1999-03-08 2000-09-14 Genentech, Inc. Activation ou inhibition de l'angiogenese et de la cardiovascularisation
CA2270908A1 (fr) 1996-11-08 1998-05-22 Human Genome Sciences, Inc. Facteur de croissance 3 du tissu conjonctif
EP0996724A1 (fr) * 1997-06-19 2000-05-03 Incyte Pharmaceuticals, Inc. Polynucleotides codant une proteine de type facteur de croissance
US20020192209A1 (en) * 1997-09-17 2002-12-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US6387657B1 (en) * 1997-10-29 2002-05-14 Genentech, Inc. WISP polypeptides and nucleic acids encoding same
WO1999062927A1 (fr) * 1998-06-05 1999-12-09 Human Genome Sciences, Inc. Facteur de croissance 4 du tissu conjonctif
KR100342045B1 (ko) * 1999-04-16 2002-06-27 김순택 2차전지
AU6088900A (en) * 1999-07-23 2001-02-13 Case Western Reserve University Novel methods and reagents useful in the treatment of osteoarthritis
US20020063763A1 (en) * 2000-11-29 2002-05-30 Mantell David Allen Apparatus and method for removing air bubbles from an ink jet printhead
GB9930768D0 (en) 1999-12-29 2000-02-16 Pfizer Ltd Composition
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
CA2425145C (fr) * 2000-10-16 2011-08-30 Genentech, Inc. Procedes de traitement utilisant des polypeptides wisp

Also Published As

Publication number Publication date
WO2002033085A3 (fr) 2003-04-17
ATE456655T1 (de) 2010-02-15
EP2180053A3 (fr) 2010-11-10
EP1927659B1 (fr) 2010-01-27
DE60133301T2 (de) 2009-05-14
EP1326980A2 (fr) 2003-07-16
EP2180053A2 (fr) 2010-04-28
ATE544855T1 (de) 2012-02-15
DE60141236D1 (de) 2010-03-18
AU2437702A (en) 2002-04-29
ES2381935T3 (es) 2012-06-01
US20050054563A1 (en) 2005-03-10
WO2002033085A2 (fr) 2002-04-25
JP2004534720A (ja) 2004-11-18
AU2002224377B2 (en) 2007-07-19
IL200484A (en) 2012-05-31
IL155279A (en) 2011-05-31
CA2425145A1 (fr) 2002-04-25
AU2002224377B8 (en) 2002-04-29
IL200484A0 (en) 2010-04-29
ES2304401T3 (es) 2008-10-16
WO2002033085A9 (fr) 2002-07-25
CA2425145C (fr) 2011-08-30
US20100093628A1 (en) 2010-04-15
EP1927659A1 (fr) 2008-06-04
EP1326980B1 (fr) 2008-03-19
JP4202128B2 (ja) 2008-12-24
US7687460B2 (en) 2010-03-30
EP2180053B1 (fr) 2012-02-08
US8138152B2 (en) 2012-03-20
DE60133301D1 (de) 2008-04-30
ATE389719T1 (de) 2008-04-15
ES2338492T3 (es) 2010-05-07

Similar Documents

Publication Publication Date Title
IL200484A0 (en) Use of wisp polypeptides wisp for the preparation of medicaments
AU4935701A (en) Use of insulin for the treatment of cartilagenous disorders
TW366342B (en) The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
ATE338569T1 (de) Osteogene vorrichtungen und verfahren zu ihrer verwendung zur knochenreparatur
MX9602818A (es) Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige.
DE69433530D1 (de) Bmp-11 zusammensetzungen
WO2004019884A3 (fr) Agents et procedes pour stimuler la formation osseuse
ATE362766T1 (de) Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen
FR13C0062I1 (fr)
PL331922A1 (en) Method of inhibiting fibrosis by means of an antagonist of somatotropin release inhibiting factor
ES2182902T3 (es) Sistema de reparacion de superficies de articulaciones.
DE69729125D1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
EA200400734A1 (ru) Способ и композиция для потенциирования действия опиатного анальгетика
PT946190E (pt) Metodos e composicoes para estimular o crescimento de neurites
DE60140960D1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DE69821793D1 (de) Neuronale verwendungen des bmp-11
WO2002092013A3 (fr) Methodes de traitement des maladies du foie et des lesions du foie a l'aide de l'hormone de croissance et de la proteine foxm1b
IT1293305B1 (it) Sali di acidi difosfonici e loro impiego farmacologico nel trattamento dell'osteoporosi
ES2196349T3 (es) Uso de galanina para reparar lesiones en los nervios.
WO1997048368A3 (fr) Naphtyridines affectant le recepteur il-4 et le facteur g-csf
RU98103720A (ru) Способ лечения идиопатического асептического некроза головки бедра у детей
BR9709007A (pt) Uso de azaspirano substituìdo no tratamento da asma.